Experimental drug ADI-PEG20 increased mesothelioma survival by 1.6 months and quadrupled three-year survival rate when combined with chemo, according to a clinical trial.

An experimental drug, ADI-PEG20, has shown promising results in treating malignant mesothelioma, a rare cancer linked to asbestos exposure. In a clinical trial involving 249 patients, the drug increased average survival of mesothelioma patients by 1.6 months and quadrupled the three-year survival rate when combined with traditional chemotherapy. The drug's effectiveness has been attributed to the arginine starvation of cancer cells.

February 15, 2024
8 Articles